References

Filters: Akiyama-2019b is   [Clear All Filters]
F
Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599-2607.
Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5(7):649-657.
Feld JJ, Moreno C, Trinh R. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol . 2016;64(2):301-307.
Feng HP, Caro L, Dunnington KM, et al. A clinically meaningful drug-drug interaction observed between Zepatier (Grazoprevir/Elbasvir) and Stribild HIV fixed dose combination in healthy subjects [Abstract O-22]. In: International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. June 8-10. International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. June 8-10.; 2016.
Feng HP, Guo Z, Ross L, et al. Assessment of drug interaction potential between the direct-acting antiviral agents elbasvir/grazoprevir and integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 2019;74(3):710-717.
Feng HP, Guo Z, Fandozzi C, et al. Pharmacokinetic interactions between the fixed-dose combinations of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and elbasvir/grazoprevir in healthy adult participants. Clin Pharmacol Drug Dev. 2019;8(7):952-961. doi:10.1002/cpdd.702.
Feng HP, Guo Z, Caro L, et al. Assessment of drug interaction potential between the hepatitis C virus direct-acting antiviral agents elbasvir/grazoprevir and the nucleotide analog reverse-transcriptase inhibitor tenofovir disoproxil fumarate. Clin Pharmacol Drug Dev. 2019;8(7):962-970.
Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992.
Fernandez N, Towers CV, Wolfe L, Hennessy MD, Weitz B, Porter S. Sharing of snorting straws and hepatitis C virus infection in pregnant women. Obstet and Gynecol. 2016;128(2):234-237.
Fernandez-Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the HEPA-C registry. J Hepatology . 2016;64(2):S133. doi: http://dx.doi.org/10.1016/S0168-8278(16)64003-5.
Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis. 2008;198(5):683-686.
Fierer DS, Dieterich D, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis. 2013;56(7):1038-1043.
Fierer DS, Wyles DL. Re-treatment of hepatitis C infection after multiple failures of direct-acting antiviral therapy. Open Forum Infect Dis. 2020;7(4):ofaa095.
Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52-61.
Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275-281.
Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335-2342.
Flamm SL, Bacon B, Curry MP, et al. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther. 2018;47(11):1511-1522. doi:10.1111/apt.14635.
Flamm SL, Kort J, Marx SE, et al. Effectiveness of 8-week glecaprevir/pibrentasvir for treatment-naive, compensated cirrhotic patients with chronic hepatitis C infection. Adv Ther. 2020;37(5):2267-2274.
Flamm S, Reddy KR, Zadeikis N, et al. Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection. Clin Gastroenterol Hepatol. 2019;17(3):527-535.e6. doi:10.1016/j.cgh.2018.07.003.
Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38:e79-e80.
Top